Evidence map›Paper›PMID 37485448›Full record

ArticleFuture science OA2023

Yi Kuang, Wenjing Shen, Xiaodong Ma, Ziwei Wang, Rui Xu, Qingqing Rao, Shengxiang Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yi KuangCollege of Chemical & Materials Engineering, Zhejiang A&F University, Lin'an, 311300, Zhejiang, China.
Wenjing ShenCollege of Chemical & Materials Engineering, Zhejiang A&F University, Lin'an, 311300, Zhejiang, China.
Xiaodong MaCollege of Chemical & Materials Engineering, Zhejiang A&F University, Lin'an, 311300, Zhejiang, China.
Ziwei WangCollege of Chemical & Materials Engineering, Zhejiang A&F University, Lin'an, 311300, Zhejiang, China.
Rui XuCollege of Chemical & Materials Engineering, Zhejiang A&F University, Lin'an, 311300, Zhejiang, China.
Qingqing RaoCollege of Chemical & Materials Engineering, Zhejiang A&F University, Lin'an, 311300, Zhejiang, China.
Shengxiang YangCollege of Chemical & Materials Engineering, Zhejiang A&F University, Lin'an, 311300, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: To determine natural compounds with inhibitory effects toward SARS-CoV-2 Mpro from Chinese herbal medicines. Materials & methods: ∼1200 natural compounds from 19 Chinese herbal medicines were collected. Computational methods including molecular docking, drug-likeness assessment, molecular dynamics simulation and molecular mechanics Poisson-Boltzmann surface area analysis were combined to obtain potent inhibitors against SARS-CoV-2 Mpro. Results: Top 20 compounds mainly originated from Conclusion: Natural compound Japonicone G is highly promising as a potent inhibitor against SARS-CoV-2 for further study.

Indexed as

Chinese herbal medicineJaponicone Gmolecular dockingmolecular dynamics simulationSARS-CoV-2 Mpro

Identifiers

PMID37485448
PMCPMC10357396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.